Epilepsy

Epilepsy – High‑Yield Study Guide for Medical Students

Definition

Epilepsy is a chronic neurological disorder characterized by a persistent predisposition to generate epileptic seizures, with associated neurobiologic, cognitive, psychological, and social consequences. A practical, widely used clinical definition (ILAE) requires one of the following:

• At least two unprovoked (or reflex) seizures occurring >24 hours apart; or
• One unprovoked (or reflex) seizure and a high probability of further seizures (≥60%) over the next 10 years (e.g., due to a structural lesion or epileptiform EEG); or
• Diagnosis of an epilepsy syndrome.

Epidemiology

Epilepsy is one of the most common serious chronic neurological diseases worldwide, affecting approximately 0.6–1% of the population. Incidence is highest in childhood and in older adults. Up to one-third of patients may have drug-resistant epilepsy, defined as failure of adequate trials of two appropriately chosen and tolerated antiseizure medications (ASMs) to achieve sustained seizure freedom.^[1]

Pathophysiology

Epileptic seizures arise from abnormal, excessive, and synchronous neuronal activity in the cerebral cortex. The core pathophysiologic mechanisms involve an imbalance between excitatory (primarily glutamatergic) and inhibitory (primarily GABAergic) neurotransmission, altered ion channel function, and changes in neuronal networks.

Key mechanisms include:

• Increased excitability: Upregulation or dysfunction of voltage-gated sodium and calcium channels, increased glutamate release, or defective glutamate reuptake.
• Reduced inhibition: Impaired GABA synthesis, release, receptor function, or altered chloride homeostasis.
• Network reorganization: After insults such as trauma, stroke, infection, or genetic channelopathies, cortical and hippocampal circuits can undergo synaptic reorganization (e.g., mossy fiber sprouting), creating epileptogenic networks.
• Genetic factors: Pathogenic variants in ion-channel genes (e.g., SCN1A), synaptic proteins, or cell adhesion molecules (e.g., PCDH19) underlie many developmental and epileptic encephalopathies, modifying neuronal excitability and network synchronization.^[1]

In focal epilepsies, abnormal discharges begin in a discrete cortical region (epileptogenic zone) and may remain localized or spread to involve both hemispheres. In generalized epilepsies, seizures appear to arise within and rapidly engage networks distributed across both hemispheres from onset.

Clinical Presentation

Clinical manifestations depend on seizure type and underlying etiology. A precise seizure classification is central to diagnosis and management.

Seizure Classification (ILAE-style, simplified)

• Focal onset seizures (originate in one hemisphere)
  • Focal aware (formerly simple partial): Awareness preserved; symptoms depend on cortical area (e.g., focal motor clonic jerks, sensory phenomena, autonomic symptoms, psychic symptoms such as déjà vu).
  • Focal impaired awareness (formerly complex partial): Altered awareness, behavioral arrest, automatisms (lip smacking, picking motions), postictal confusion.
  • Focal to bilateral tonic–clonic: Focal onset with subsequent spread to bilateral tonic–clonic activity.
• Generalized onset seizures (engage networks in both hemispheres from onset)
  • Absence: Brief (usually <15 s) staring spells, impaired awareness, eyelid flutter or simple automatisms, abrupt onset and termination, classically with 3 Hz spike-and-wave on EEG.
  • Generalized tonic–clonic (GTCS): Sudden loss of consciousness, tonic stiffening followed by clonic jerking, tongue biting (lateral), possible incontinence, postictal confusion and myalgia.
  • Myoclonic: Brief, shock-like muscle jerks, often in the morning, can occur in clusters; commonly seen in juvenile myoclonic epilepsy.
  • Atonic: Sudden loss of muscle tone, leading to head drop or falls (drop attacks), typical in Lennox–Gastaut syndrome.
  • Tonic: Sudden increased tone with posturing, often occurring out of sleep.
• Unknown onset seizures: When onset is not observed or unclear (e.g., unwitnessed nocturnal events).

Epilepsy Syndromes

Epilepsy can be further classified into specific syndromes based on age at onset, seizure types, EEG patterns, imaging findings, and comorbidities. Examples include childhood absence epilepsy, juvenile myoclonic epilepsy, temporal lobe epilepsy, Lennox–Gastaut syndrome, and genetic epileptic encephalopathies such as PCDH19-related epilepsy.^[1]

Associated Features

• Postictal state: Transient confusion, fatigue, headache, focal neurological deficits (e.g., Todd paralysis) after focal or generalized tonic–clonic seizures.
• Cognitive and psychiatric comorbidities: Attention deficits, learning difficulties, mood and anxiety disorders, psychosis, and subjectively perceived cognitive dysfunction; the latter may show only modest correlation with objective testing and requires careful evaluation.^[2]
• Developmental delay / regression: Particularly in early-onset developmental and epileptic encephalopathies.

Diagnosis

Diagnosis relies on a careful history, eyewitness account, and targeted investigations. The main goal is to confirm epileptic seizures, classify seizure type and syndrome, and identify an underlying cause.

1. History and Examination

• History of the event: Prodrome or aura, onset (focal vs generalized), motor phenomena, automatisms, autonomic signs, duration, postictal features, triggers (sleep deprivation, flashing lights, fever, odors, hyperventilation, alcohol, missed medications). Odors are notable, as olfactory stimuli can in some cases precipitate or modulate seizures via limbic circuits.^[3]
• Past medical history: Perinatal injury, CNS infections, trauma, stroke, tumors, neurocutaneous syndromes, metabolic disease.
• Medication and substance history: Proconvulsant drugs, alcohol, recreational drugs.
• Family history: Epilepsy, febrile seizures, known genetic syndromes.
• Neurologic exam: Often normal between seizures; look for focal deficits, neurocutaneous stigmata, developmental delay.

2. Electroencephalography (EEG)

• Interictal EEG: Looks for epileptiform discharges (spikes, sharp waves, spike-and-wave complexes). Helps classify seizure type and identify specific syndromes (e.g., 3 Hz generalized spike-and-wave pattern in childhood absence epilepsy).
• Video-EEG monitoring: Gold standard for differentiating epileptic seizures from functional (psychogenic) seizures and other paroxysmal events; also essential in pre-surgical evaluation. Observational awareness of functional seizures must remain empathic to avoid stigmatizing behaviors such as inappropriate laughter.^[4]

3. Neuroimaging

• Brain MRI with epilepsy protocol is recommended in most patients with focal seizures or focal neurologic signs, and in adults with new-onset epilepsy. It detects structural lesions such as hippocampal sclerosis, cortical dysplasia, tumors, vascular malformations, or post-traumatic scarring.
• CT head is used in the acute setting to exclude hemorrhage or large lesions when MRI is not immediately available.

4. Laboratory and Additional Workup

• Basic labs: Serum glucose, electrolytes (Na, Ca, Mg), renal and hepatic function, toxicology screen when appropriate.
• Metabolic / genetic testing: Consider in early-onset, developmental epileptic encephalopathies, or when systemic signs suggest an inherited metabolic disorder. Myoclonus in children, for example, may be a key manifestation of an underlying metabolic disease that is potentially treatable.^[5]
• CSF studies: If CNS infection, autoimmune encephalitis, or inflammatory etiology is suspected.

Management

Management aims for seizure freedom with minimal adverse effects, tailored to seizure type, epilepsy syndrome, and patient-specific factors (age, comorbidities, pregnancy plans, drug interactions).

General Principles

• Confirm diagnosis and classify seizure type and epilepsy syndrome before long-term treatment.
• Address provoking factors (sleep deprivation, alcohol, metabolic disturbances, offending drugs).
• Begin antiseizure medication (ASM) when there is a high risk of recurrence (e.g., after two unprovoked seizures, or after one seizure with epileptiform EEG and a structural lesion).
• Start with monotherapy at a low dose and titrate upward until seizures are controlled or adverse effects occur.

Choice of Antiseizure Medications (ASMs)

Focal onset seizures (and focal to bilateral tonic–clonic):

• First-line options (depending on guidelines and region): levetiracetam, lamotrigine, carbamazepine, oxcarbazepine, or lacosamide.
• Levetiracetam and lamotrigine are often favored due to broad spectrum of efficacy and relatively favorable side-effect profiles.

Generalized tonic–clonic seizures (primary generalized):

• Valproate is highly effective but is teratogenic and should be avoided or used with great caution in women of childbearing potential; alternatives include levetiracetam, lamotrigine, and topiramate in appropriate contexts.

Absence seizures:

• Ethosuximide is first-line for typical absence seizures; valproate or lamotrigine may be used if GTCS co-exist.

Myoclonic seizures / juvenile myoclonic epilepsy:

• Valproate is very effective; alternatives include levetiracetam, topiramate, or zonisamide depending on patient factors.

Drug-Resistant Epilepsy

About one-third of patients have drug-resistant epilepsy; management requires a stepwise approach and often a tertiary epilepsy center.

• Reassess diagnosis and adherence: Confirm epileptic nature of events, optimize doses, check for interactions, and address lifestyle factors.
• Surgical evaluation: Candidates with focal drug-resistant epilepsy due to a resectable lesion (e.g., mesial temporal sclerosis, focal cortical dysplasia) may achieve seizure freedom with resective surgery or laser ablation.
• Neurostimulation: Vagus nerve stimulation (VNS), responsive neurostimulation (RNS), or deep brain stimulation (DBS) can reduce seizure frequency when surgery is not feasible.
• Dietary therapy: Ketogenic diet or modified Atkins diet is especially useful in children with refractory epilepsy and certain metabolic or genetic epilepsies.
• Investigational and adjunctive approaches: Novel agents, including nanoformulations of compounds like curcumin, are being explored as adjuncts in drug-resistant epilepsy, targeting oxidative stress and neuroinflammatory pathways.^[6]
• In specific genetic epilepsies such as PCDH19-related epilepsy, management remains challenging, and current strategies rely on consensus-based recommendations derived from systematic reviews and expert panels to guide ASM choice and syndrome-specific interventions.^{[1], [7]}

Status Epilepticus (Brief Overview)

Status epilepticus is a neurological emergency defined as prolonged seizure activity (for convulsive status, ≥5 minutes of continuous seizure or recurrent seizures without full recovery). Initial management priorities include airway protection, rapid IV benzodiazepine administration (e.g., lorazepam), followed by loading with an IV ASM (e.g., levetiracetam, fosphenytoin, valproate) and identification of underlying causes. Detailed protocols are typically guided by national or international consensus recommendations.^[7]

Non‑pharmacologic and Supportive Management

• Education and counseling: Seizure first aid, adherence, sleep hygiene, avoidance of precipitants, safety measures (e.g., driving restrictions per local laws, swimming precautions).
• Psychosocial support: Address stigma, mood disorders, anxiety, and quality of life; involve caregivers and families.
• Reproductive counseling: Preconception planning, folate supplementation, and ASM selection in women of childbearing age.
• Comorbidity management: Cognitive dysfunction, psychiatric comorbidities, and sleep disorders should be actively investigated and treated, given the often discordant relationship between subjective complaints and objective performance.^[2]

Key Clinical Pearls

• Classify seizure type accurately (focal vs generalized, aware vs impaired awareness) since treatment choices and prognosis differ.
• One unprovoked seizure ≠ automatic lifelong epilepsy diagnosis; assess recurrence risk (EEG, imaging, etiology) before committing to long-term therapy.
• An apparently generalized tonic–clonic seizure may start focally: Ask about aura and early focal signs to detect focal to bilateral tonic–clonic seizures.
• Always consider structural and metabolic etiologies in new-onset seizures, especially in adults and children with myoclonus or developmental delay, as some metabolic epilepsies are treatable.^[5]
• Not all paroxysmal events are epileptic: Differentiate syncope, movement disorders, sleep disorders, and functional seizures; video-EEG is key when the diagnosis is uncertain.^[4]
• Be cautious with ASM selection: Certain narrow-spectrum ASMs (e.g., carbamazepine, phenytoin) can worsen some generalized epilepsies (myoclonic or absence seizures).
• Drug-resistant epilepsy requires early referral to an epilepsy center for multidisciplinary evaluation (surgery, neuromodulation, dietary therapy, and genetic workup).
• Emerging therapies and consensus-based recommendations are especially important in rare genetic epilepsies where high-level randomized evidence is limited, underscoring the role of well-conducted expert Delphi processes and systematic reviews in guiding care.^{[7], [1]}
• Epilepsy care is not just about seizures: Always screen for cognitive, psychiatric, and psychosocial issues, which significantly affect quality of life and may not correlate with seizure frequency alone.^[2]

Summary

Epilepsy is a common, heterogeneous chronic brain disorder defined by a predisposition to generate epileptic seizures. Effective care requires accurate seizure and syndrome classification, systematic search for underlying causes, thoughtful ASM selection, and attention to drug-resistant cases, where advanced therapies and consensus-based recommendations are crucial. Beyond seizure control, clinicians must address cognitive, psychiatric, and social dimensions to optimize long-term outcomes for people living with epilepsy.^{[1], [2]}